Finoriq research workspace
AbCellera Biologics Inc. (ABCL) Insider Transactions & Form 4 Activity
Track insider acquisitions, dispositions, options, RSUs, and Form 4 activity for AbCellera Biologics Inc. (ABCL).
Company Snapshot
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; and partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.
- Company
- AbCellera Biologics Inc. (ABCL)
- Ticker
- ABCL
- Market Cap
- $1.7B
- Latest Price
- $5.855
- Industry
- Biotech & Pharma
AbCellera Biologics Inc. (ABCL) Recent Insider Transactions
Recent market insider transaction records indexed for AbCellera Biologics Inc. (ABCL).
| Insider | Code | Value | Transaction Date |
|---|---|---|---|
| Thermopylae Holdings Ltd.Common Shares | P | Acquired | $130,720 | 2026-02-27 |
| Booth AndrewChief Financial Officer | P | Acquired | $145,692 | 2026-02-27 |
| Thermopylae Holdings Ltd.Common Shares | P | Acquired | $580,284 | 2026-02-26 |
| Montalbano John S.Common Shares | P | Acquired | $178,460 | 2025-11-26 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.